InvestorsHub Logo
Followers 0
Posts 7
Boards Moderated 0
Alias Born 04/23/2014

Re: None

Wednesday, 05/14/2014 2:35:03 AM

Wednesday, May 14, 2014 2:35:03 AM

Post# of 347753

Statement of Changes in Beneficial Ownership (4)







Print



FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940







1. Name and Address of Reporting Person *

NARINE JEENARINE 2. Issuer Name and Ticker or Trading Symbol

ELITE PHARMACEUTICALS INC /NV/ [ ELTP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director __ X __ 10% Owner
_____ Officer (give title below) _____ Other (specify below)


(Last) (First) (Middle)


C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE 3. Date of Earliest Transaction (MM/DD/YYYY)


5/9/2014


(Street)


LAURELTON, NY 11413
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)



6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person



Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Common Stock 5/9/2014 S 329437 D $0.3823 5510455 D



Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares




Explanation of Responses:


Reporting Owners

Reporting Owner Name / Address
Relationships

Director 10% Owner Officer Other
NARINE JEENARINE
C/O EPIC PHARMA, LLC
227-15 NORTH CONDUIT AVENUE
LAURELTON, NY 11413 X X




Signatures

Jeenarine Narine 5/13/2014
** Signature of Reporting Person Date